Update: Webcast of Advaxis Presentation at Jefferies 2017 Global Healthcare Conference Now Available

PRINCETON, N.J.–(BUSINESS WIRE)– Advaxis,
Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing
cancer immunotherapies, announced that Daniel J. O’Connor, President and
Chief Executive Officer of Advaxis, presented a company overview today
at the Jefferies
2017 Global Healthcare Conference in New York, NY.

An archived webcast of the presentation is available at http://wsw.com/webcast/jeff105/adxs.

About Advaxis, Inc.

Located in Princeton, N.J., Advaxis, Inc. is a biotechnology company
developing multiple cancer immunotherapies based on its proprietary Lm Technology™.
Lm Technology, using bioengineered live attenuated Listeria
monocytogenes (Lm) bacteria, is the only known cancer
immunotherapy agent shown in preclinical studies to both generate cancer
fighting T cells directed against cancer antigens and neutralize Tregs
and myeloid-derived suppressor cells (MDSCs) that protect the tumor
microenvironment from immunologic attack and contribute to tumor growth.
Advaxis’ lead Lm Technology immunotherapy, axalimogene
filolisbac, targets HPV-associated cancers and is currently has multiple
clinical trials underway, including Phase 3 in invasive cervical cancer,
Phase 2 in head and neck cancer, and Phase 2 in anal cancer. The FDA has
granted axalimogene filolisbac orphan drug designation for each of these
three clinical settings, as well as Fast Track designation for adjuvant
therapy for high-risk, locally advanced cervical cancer (HRLACC)
patients and a Special Protocol Assessment agreement for the Phase 3
AIM2CERV trial in HRLACC patients. Axalimogene filolisbac has also been
classified as an advanced therapy medicinal product for the treatment of
cervical cancer by the European Medicines Agency’s Committee for
Advanced Therapies. Advaxis has two additional immunotherapy products:
ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid
tumors, in human clinical development. In addition, Advaxis and Amgen
are developing ADXS-NEO, an investigational cancer immunotherapy
treatment designed to activate a patient’s immune system to respond
against the unique mutations, or neoepitopes, contained in and
identified from each individual patient’s tumor, with plans to enter the
clinic in 2017.

To learn more about Advaxis, visit www.advaxis.com
and connect on Twitter,
LinkedIn,
Facebook,
and YouTube.

Advaxis Forward-Looking Statement

This press release contains forward-looking statements, including, but
not limited to, statements regarding Advaxis’ ability to develop the
next generation of cancer immunotherapies, and the safety and efficacy
of Advaxis’ proprietary immunotherapy, axalimogene filolisbac. These
forward-looking statements are subject to a number of risks including
the risk factors set forth from time to time in Advaxis’ SEC filings
including, but not limited to, its report on Form 10-K for the fiscal
year ended October 31, 2016, which is available at http://www.sec.gov.

Any forward-looking statements set forth in this presentation speak only
as of the date of this presentation. We do not intend to update any of
these forward-looking statements to reflect events or circumstances that
occur after the date hereof other than as required by law.

You are cautioned not to place undue reliance on any forward-looking
statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170608005702/en/